(Q61641127)

English

NOVEL STRATEGIES TOWARD THE DEVELOPMENT OF AN EFFECTIVE VACCINE TO PREVENT HUMAN IMMUNODEFICIENCY VIRUS INFECTION OR ACQUIRED IMMUNODEFICIENCY VIRUS*

article

In more languages

Statements

scholarly article

0 references

NOVEL STRATEGIES TOWARD THE DEVELOPMENT OF AN EFFECTIVE VACCINE TO PREVENT HUMAN IMMUNODEFICIENCY VIRUS INFECTION OR ACQUIRED IMMUNODEFICIENCY VIRUS* (English)

0 references

1

object named as

Barbara Ensoli

0 references

author name string

Aurelio Cafaro

2

0 references

publication date

January 2001

0 references

Clinical Research and Regulatory Affairs

0 references

18

0 references

4

0 references

293-327

0 references

A vaccine for HIV type 1: the antibody perspective

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

HIV-1 neutralizing antibodies: how full is the bottle?

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

IgG surfaces as an important component in mucosal protection

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Vaccines and the induction of functional antibodies: time to look beyond the molecules of natural infection?

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Importance of the nef gene for maintenance of high virus loads and for development of AIDS

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Live attenuated simian immunodeficiency virus prevents super-infection by cloned SIVmac251 in cynomolgus monkeys

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Vaccine developments

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Effects of TH1 and TH2 cytokines on CD8+ cell response against human immunodeficiency virus: implications for long-term survival

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNA

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

In vivo migration and function of transferred HIV-1-specific cytotoxic T cells

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Vaccination with Rev and Tat against AIDS.

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Alloimmunization for immune-based therapy and vaccine design against HIV/AIDS.

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells.

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Protection from pathogenic SIVmac challenge following short-term infection with a nef-deficient attenuated virus

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Mechanisms of protection induced by attenuated simian immunodeficiency virus. I. Protection cannot be transferred with immune serum.

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Mechanisms of protection induced by attenuated simian immunodeficiency virus. II. Lymphocyte depletion does not abrogate protection.

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Long-lasting protection by live attenuated simian immunodeficiency virus in cynomolgus monkeys: no detection of reactivation after stimulation with a recall antigen.

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

CD8+ cell-derived anti-human immunodeficiency virus inhibitory factor

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Phosphoantigen-reactive Vgamma9Vdelta2 T lymphocytes suppress in vitro human immunodeficiency virus type 1 replication by cell-released antiviral factors including CC chemokines

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Molecular cloning and expression of rhesus macaque and sooty mangabey interleukin 16: biologic activity and effect on simian immunodeficiency virus infection and/or replication

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Recombinant human CD40 ligand inhibits simian immunodeficiency virus replication: a role for interleukin- 16.

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

T lymphocyte responses in HIV-1 infection: implications for vaccine development

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Applications of pox virus vectors to vaccination: an update

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA.

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Efficacy studies on a canarypox-rabies recombinant virus

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Recombinant subunit vaccines as an approach to study correlates of protection against primate lentivirus infection

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Sindbis virus vectors for expression in animal cells

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Alphavirus-based expression vectors: strategies and applications

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Sindbis virus: an efficient, broad host range vector for gene expression in animal cells

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

A new generation of animal cell expression vectors based on the Semliki Forest virus replicon

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates.

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus.

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

An HLA-based approach to the design of a CTL-inducing vaccine against Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Suppressive effect of antibody on processing of T cell epitopes

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Enhancement of disease by neutralizing antiviral antibodies in the absence of primed antiviral cytotoxic T cells

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Modulation of antigen processing by bound antibodies can boost or suppress class II major histocompatibility complex presentation of different T cell determinants

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Induction of protective cytotoxic T cell responses in the presence of high titers of virus-neutralizing antibodies: implications for passive and active immunization

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Trans-activator gene of human T-lymphotropic virus type III (HTLV-III).

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

The trans-activator gene of HTLV-III is essential for virus replication

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Regulation of Cellular Gene Expression and Function by the Human Immunodeficiency Virus Type 1 Tat Protein

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Cellular uptake of the tat protein from human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Tat protein induces self-perpetuating permissivity for productive HIV-1 infection

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1.

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120.

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS.

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1.

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS.

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

The envelope glycoprotein ectodomains determine the efficiency of CD4+ T lymphocyte depletion in simian-human immunodeficiency virus-infected macaques

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Tat toxoid as a component of a preventive vaccine in seronegative subjects

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Analysis of T helper and antigen-presenting cell functions in cord blood and peripheral blood leukocytes from healthy children of different ages.

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Alloimmunization to prevent AIDS?

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Immunotherapy for recurrent miscarriage

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Major histocompatibility complex class I-associated vaccine protection from simian immunodeficiency virus-infected peripheral blood cells.

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

AIDS vaccine developments

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

AIDS vaccine developments

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

AIDS vaccine developments

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

CD8-suppressor factor and beta-chemokine function as a complementary mechanism to cognate immunity

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

AIDS preclinical vaccine development: biennial survey of HIV, SIV, and SHIV challenge studies in vaccinated nonhuman primates

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Effect of antigen/antibody ratio on macrophage uptake, processing, and presentation to T cells of antigen complexed with polyclonal antibodies

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

A rational basis for mucosal vaccination against HIV infection

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Protection against mucosal SIVsm challenge in macaques infected with a chimeric SIV that expresses HIV type 1 envelope

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Progress towards a vaccine to prevent sexual transmission of HIV.

1 reference

https://api.crossref.org/works/10.1081%2FCRP-100108179

21 January 2018

Fusion-competent vaccines: broad neutralization of primary isolates of HIV

1 reference

3 January 2024

https://opencitations.net/index/api/v1/citations/10.1126/SCIENCE.283.5400.357

Identifiers

10.1081/CRP-100108179

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q61641127&oldid=2045231513"